The recent news about peptide reclassification has introduced a lot of new vocabulary. Category 1. Category 2. Compounding status. Enforcement discretion.
If you're not a pharmacist or a regulatory attorney, it can be hard to know what any of it actually means for you as a patient.
Here's the plain-English version.
Before the category system makes sense, it helps to understand what compounding pharmacies are.
Compounding pharmacies are licensed facilities that prepare customized medications — including injectable compounds — for individual patients under a physician's prescription. They operate under regulatory oversight and quality standards that unregulated online sellers are not subject to.
When you access a peptide through a licensed compounding pharmacy with a physician's prescription, you're getting a pharmaceutical-grade product from an inspected facility. That's a very different experience from purchasing a "research use only" product from an online vendor with no oversight.
Category 1 is the designation for bulk drug substances that compounding pharmacies are permitted to use in preparing individualized medications.
According to the FDA, substances in Category 1 are those that "do not appear to present a significant safety risk in compounding at this time" — meaning the agency does not intend to take action against licensed compounders for preparing them, provided all other applicable legal requirements are met.
If a peptide is on the Category 1 list, a licensed physician can prescribe it, a licensed compounding pharmacy can prepare it, and a patient can legally receive it. The compound still isn't an FDA-approved drug — but it has a clear, legal, regulated pathway to access.
Category 2 is the restricted designation. Substances placed in Category 2 have been identified by the FDA as raising significant safety concerns — which means compounding pharmacies generally cannot prepare them under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
In 2023, the FDA moved 19 widely used peptides to Category 2. For patients who had been using these compounds under physician supervision, access through legal channels effectively disappeared overnight.
The FDA's stated rationale for the Category 2 placements included concerns about immunogenicity, impurities, and gaps in long-term safety data.
Many clinicians and compounding pharmacy groups pushed back. Their argument: for most of the affected peptides, no specific safety signal justified the restriction. And in practice, the restrictions didn't eliminate patient demand — they redirected it toward gray-market and unregulated sources, which carry far greater real-world risk.
That argument ultimately gained traction. In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 restricted peptides are expected to return to Category 1, citing the absence of a required safety signal for most of them. Kennedy acknowledged directly that the 2023 restrictions had created the very gray market the FDA was ostensibly trying to protect patients from.
Category 1 reclassification is not FDA approval. FDA drug approval is a separate, rigorous process involving large-scale clinical trials demonstrating safety and efficacy for a specific indication. Most of these peptides have not gone through that process, and reclassification doesn't change that.
What reclassification does mean is that these compounds can once again be legally prepared by licensed compounding pharmacies under physician prescription — restoring safe, regulated access that had been shut off for most of the past two years.
This is the most important part: the reclassification has been announced but not yet formalized. As of this writing, the FDA has not published its updated compounding list. The peptides discussed throughout this blog series remain on the Category 2 restricted list until that formal publication occurs.
This means none of them are currently legally available through licensed compounding pharmacies in the United States. Any source offering these compounds today — online or otherwise — is operating outside current legal compounding guidelines.
The right move is to connect with a licensed provider now, understand your options, and be ready to move forward when the formal update is published.
Belle's currently available programs are a good starting point. As the regulatory landscape evolves, we'll be expanding what we offer.
Explore Belle's currently available programs.
Belle offers provider-guided compounded medication programs. Peptide compounds are not FDA-approved drugs. Access requires a licensed provider's prescription. Always work with a qualified medical professional before beginning any new therapy.
